Archive: 2 10 2016
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma …
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic…
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a …
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic …
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinica…
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome Limited data are available on major bleeding (MB) occurring during treatment with vitamin K…
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s.
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treate…
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has…
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT…
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER! We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is…
EHA Award winners put in the spotlight in Copenhagen
Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.